Essent Biologics Introduces Human Demineralized Bone Matrix (DBM) Bioink For 3D Bioprinting And Tissue Engineering Research Applications

CENTENNIAL, Colo., Sept. 21, 2021 - Essent Biologics™, a nonprofit biotechnology company, today announced the launch of its spectral demineralized bone matrix (DBM), first of its kind, human-derived DBM for 3D bioprinting and tissue engineering research applications. Essent Biologics will provide an osteoconductive DBM powder with osteoinductive potential derived from adult human cortical bone.

The company's DBM powder is specifically formulated for bone tissue engineering research, complex in vitro bone models for drug discovery and other regenerative medicine research applications for musculoskeletal tissue. The product is an acid-extracted organic matrix from human bone and retains much of the components native to bone, such as calcium-based solids, inorganic phosphates and some trace of cell debris.

"We are excited to launch our first scaffold product for the regenerative medicine space," said Corey Stone, President, Essent Biologics. "Our DBM will support research efforts for next generation bone therapeutics, produce validated utility, and demonstrate opportunities to enhance outcomes in bone repair."

DBM is a biomaterial used in bone defects with a long track record of clinical use in diverse forms. Essent Biologics' DBM for research use is the ideal particle size for extrusion 3D bioprinting at 125-355µ particle size, recovered and processed without the use of animal products and tested for sterility and residual moisture.

For additional information on the company's product pipeline, please visit